Drugs / GIM-531
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06425926 | May 2024 → Dec 2026 expected | metastatic melanoma | Georgiamune Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-29 | Georgiamune Inc | Regulatory Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch georgiamune.com ↗
Georgiamune receives U.S. FDA clearance for GIM-531 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-07-30 | Georgiamune Inc | Georgiamune Announces First Patient Dosed in A First-In-Class Phase 1 Cancer Treatment Trial of GIM-531 georgiamune.com ↗ |
| 2024-05-29 | Georgiamune Inc | Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch georgiamune.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIM-531 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06425926 ↗ |
| Action | Inhibit | “GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).” NCT06425926 ↗ |
| Modality | Small molecule | “orally bioavailable small molecule” NCT06425926 ↗ |
| Route | Oral | “GIM-531 administered orally daily” NCT06425926 ↗ |